Speakers

Clinicians

Andrew Dillin, PhD; Associate Professor and Pioneer Developmental Chair of Molecular and Cell Biology Laboratory, Salk Institute

Investors/Analysts

Joseph Amprey, MD, PhD; Senior Managing Director, MedImmune Ventures, Inc.

Stephen Knight, MD; Managing Partner, Fidelity Biosciences

Ronald W. Lennox, D.Phil; Founder and Partner, CHL Medical Partners

Christopher K. Mirabelli, PhD; Managing Director, HealthCare Ventures

David Mott; General Partner, New Enterprise Associates

Amir Nashat, PhD; General Partner, Polaris Venture Partners

Heather Preston, MD; Managing Director, TPG Biotech

Bruce Robertson, PhD; Managing Director, H.I.G. Ventures

Scott M. Rocklage, PhD; Managing Partner, 5AM Ventures

Steven D. Weinstein; Managing Director, Novartis Venture Fund

Matt Young; Managing Director, US Life Sciences, Barclays Capital

Industry

Jeffrey A. Baumel; Partner and Chair of Corporate Life Sciences Practice, Sonneschein, Nath & Rosenthal LLP

Brian R. Dixon, PhD; President and CEO, BioRelix, Inc.

Christopher D. Earl, PhD; President and CEO, BIO Ventures for Global Health (BVGH) and former Managing Director, Perseus-Soros BioPharmaceuticals Fund, LP (PSBF)

Tuan Ha-Ngoc; President and CEO, AVEO Pharmaceuticals Inc.

Gregory J. LaRosa, PhD; Vice President, Biology, BIKAM Pharmaceuticals, Inc.

Richard Labaudinière, PhD; President and CEO, FoldRx Pharmaceuticals, Inc.

Scott Sarazen; Global Biotechnology Markets Leader, Ernst & Young

Steven Tregay, PhD; Founder, President and CEO, Forma Therapeutics

Christoph Westphal; CEO, Sirtris & Sr. VP, CEEDD, GSK